Using gene transfer technologies to reprogram adult human kidney cells could lead to novel therapies for chronic kidney disease.

Raymond Harris, MD, Ann and Roscoe R. Robinson Professor of Nephrology and director of the Vanderbilt Center for Kidney Disease, has been appointed co-chair of the American Society of Nephrology’s (ASN) Kidney Health Initiative (KHI).

Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.

Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.

Jun. 28, 2018—T. Alp Ikizler, MD, an internationally known expert on the nutritional and metabolic aspects of kidney disease, will succeed Raymond Harris, MD, as director of the Department of Medicine’s Division of Nephrology and Hypertension in the Vanderbilt University School of Medicine effective July 1.

Treatment of anemia caused by chronic kidney disease or other diseases often requires repeated — and costly — injections or infusions of an artificial form of the hormone erythropoietin (EPO), which stimulates production of red blood cells.